Drug firm prosecuted for distributing opioids illegallyA US-based drug distribution company and two former executives are being prosecuted for transporting medicines to pharmacies allegedly Share XDrug firm prosecuted for distributing opioids illegallyhttps://pharmaphorum.com/news/drug-firm-prosecuted-for-distributing-opioids-illegally/
Researchers use AI to analyse voices and diagnose PTSDArtificial intelligence could be used to diagnose post-traumatic stress disorder (PTSD), according to preliminary study findings. Assessment of Share XResearchers use AI to analyse voices and diagnose PTSDhttps://pharmaphorum.com/news/researchers-use-ai-to-analyse-voices-and-diagnose-ptsd/
Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
Alder gears up for migraine showdown with eptinezumab filingAlder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of Share XAlder gears up for migraine showdown with eptinezumab filinghttps://pharmaphorum.com/news/alder-gears-up-for-migraine-showdown-with-eptinezumab-filing/
Fulcrum repurposes failed GSK drug for rare diseaseGSK’s failed cardiovascular drug losmapimod looks like it might get a new lease of life after being picked Share XFulcrum repurposes failed GSK drug for rare diseasehttps://pharmaphorum.com/news/fulcrum-repurposes-failed-gsk-drug-for-rare-disease/
Psoriasis and cardio drugs drive Novartis’ Q1 salesNovartis has begun 2019 at a sprint, upgrading its sales forecasts for the year after strong performances from Share XPsoriasis and cardio drugs drive Novartis’ Q1 saleshttps://pharmaphorum.com/news/psoriasis-and-cardio-drugs-drive-novartis-q1-sales/
Pfizer/Lilly non-opioid pain drug shows more positive resultsResults from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can Share XPfizer/Lilly non-opioid pain drug shows more positive resultshttps://pharmaphorum.com/news/pfizer-lilly-non-opioid-pain-drug-shows-more-positive-results/
Second death in gene therapy trial prompts investigationA second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – Share XSecond death in gene therapy trial prompts investigationhttps://pharmaphorum.com/news/second-death-in-novartis-gene-therapy-trial-prompts-investigation/
FDA approves first medical device ADHD treatmentUS regulators have given the green-light for the first medical device to treat attention deficit hyperactivity disorder (ADHD). Share XFDA approves first medical device ADHD treatmenthttps://pharmaphorum.com/news/fda-approves-neurosigma-adhd/
WHO releases first guidelines on digital healthThe World Health Organization (WHO) has released new recommendations on ways that countries can use digital health technology Share XWHO releases first guidelines on digital healthhttps://pharmaphorum.com/news/who-releases-first-guidelines-on-digital-health/
The Bloc promotes Jennifer Matthews to CEO and presidentNew York-based healthcare creative agency The Bloc has promoted managing partner Jennifer Matthews to CEO and president. It’s Share XThe Bloc promotes Jennifer Matthews to CEO and presidenthttps://pharmaphorum.com/news/the-bloc-promotes-jennifer-matthews-ceo/
Redox raises $33m to build health data sharing businessHealth data firm Redox has raised $33 million as it builds its business allowing data sharing between healthcare Share XRedox raises $33m to build health data sharing businesshttps://pharmaphorum.com/news/redox-raises-33m-to-build-health-data-sharing-business/
BI chief “regrets” Brexit, but continues to invest in UKThe head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country Share XBI chief “regrets” Brexit, but continues to invest in UKhttps://pharmaphorum.com/news/bi-chief-regrets-brexit-but-continues-to-invest-in-uk/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Antibody suppresses HIV for four monthsA new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the Share XAntibody suppresses HIV for four monthshttps://pharmaphorum.com/news/antibody-suppresses-hiv-for-four-months/
Sanofi pledges €10m to Notre Dame, but faces backlashSanofi has said that it will donate 10 million Euros to the rebuilding of Notre Dame cathedral in Share XSanofi pledges €10m to Notre Dame, but faces backlashhttps://pharmaphorum.com/news/sanofi-pledges-e10m-to-notre-dame-but-faces-backlash/
Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
Hear from Amgen speaking at the 4th Pre-filled Syringes West Coast 2019 Share XHear from Amgen speaking at the 4th Pre-filled Syringes West Coast 2019https://pharmaphorum.com/partner-content/hear-from-amgen-speaking-at-the-4th-pre-filled-syringes-west-coast-2019/
Healthcare Artificial Intelligence Market will surge at 41% CAGR up to 2025 Share XHealthcare Artificial Intelligence Market will surge at 41% CAGR up to 2025https://pharmaphorum.com/partner-content/healthcare-artificial-intelligence-market-will-surge-at-41-cagr-up-to-2025/
Healthcare Analytics Market will surpass $18 Billion by 2025 Share XHealthcare Analytics Market will surpass $18 Billion by 2025https://pharmaphorum.com/partner-content/healthcare-analytics-market-will-surpass-18-billion-by-2025/
Invite from Ziva Abraham Chair – SMi’s 3rd Annual Pharma Microbiology Share XInvite from Ziva Abraham Chair – SMi’s 3rd Annual Pharma Microbiologyhttps://pharmaphorum.com/partner-content/invite-from-ziva-abraham-chair-smis-3rd-annual-pharma-microbiology/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
